Gastrointestinal Stromal Tumor (GIST) Pathology: IHC & Molecular Guide

Subtitle: A high-yield review of GIST pathology, focusing on KIT-negative variants, DOG1 sensitivity, PDGFRA mutations, and SDH-deficient diagnostic algorithms for exams.

Author: PathologyMCQ Editorial Team

Category: Gastrointestinal Pathology / Soft Tissue Tumors

Last updated: May 10, 2026

Read time: 8 minutes

This is a medical, educational, exam-oriented pathology review focused on diagnosis and histopathology.

At-a-Glance

Origin: Interstitial Cells of Cajal (ICC).
Key Markers: CD117 (KIT), DOG1, SDHB.
Key Mutations: KIT (80%), PDGFRA (10%), SDH-complex (5%).
Difficulty Level: Intermediate / Senior Resident.

1. What defines the paradigm shift in GIST diagnosis?

The diagnosis of Gastrointestinal Stromal Tumor (GIST) has evolved from a purely morphological assessment to a molecular-driven classification. While GIST is the most common mesenchymal tumor of the GI tract, approximately 5–10% of cases are KIT (CD117) negative, requiring advanced IHC markers for identification.

H&E stain showing fascicles of spindle cells in GIST.

This image demonstrates the “classic” spindle cell morphology associated with the majority of KIT-positive GISTs.
Theory Content: Most GISTs arise from the Interstitial Cells of Cajal (ICC). When CD117 is negative, pathologists must evaluate DOG1 and SDHB to identify KIT-negative molecular subsets.

2. How does the IHC Traffic Light System work?

The IHC traffic light system is a diagnostic triage tool used to categorize GIST based on the expression of CD117 and DOG1.

Comparison table of GIST variants including KIT-mutant, PDGFRA, and SDH-mutant features such as frequency, CD117, DOG1 status, SDHB integrity, morphology, location, imatinib sensitivity, age demographics, and alternative treatments.

A visual guide for triaging GIST cases into KIT-positive, PDGFRA-likely, and SDH-deficient categories.
Theory Content: Green Light indicates KIT+/DOG1+ (Classic). Yellow Light indicates KIT-/DOG1+ (suggests PDGFRA). Red Light signifies KIT-/DOG1-, necessitating SDHB testing to rule out syndromic associations.

3. What are the features of KIT-mutant GIST?

KIT-mutant GIST is the prototype of this tumor class, accounting for roughly 80% of all cases.

Histological and IHC profile of the most common GIST subtype.
Theory Content: Exon 11 mutations are most frequent (~65%) and respond well to standard Imatinib (400mg). Exon 9 mutations (found mostly in small bowel) may require higher dosages (800mg).

4. Why is PDGFRA GIST considered the epithelioid outlier?

PDGFRA-mutant GISTs frequently present with an epithelioid morphology and are predominantly located in the stomach.

Morphology of the KIT-negative gastric GIST subtype.
Theory Content: The Exon 18 (D842V) mutation is the most common and is notoriously resistant to Imatinib. Avapritinib is the targeted therapy of choice for this specific mutation.

5. How to identify Pediatric and Syndromic SDH-mutant GIST?

SDH-deficient GISTs represent a distinct clinical entity often seen in younger patients and are characterized by a loss of SDHB expression on IHC.

IHC showing the absence of SDHB protein expression in tumor cells.
Theory Content: Loss of SDHB serves as a surrogate marker for mutations in any SDH subunit. These are associated with Carney Triad (non-hereditary) and Carney-Stratakis Syndrome (hereditary).

6. Comparative Master-Table: GIST Variants

Feature	KIT-Mutant	PDGFRA-Mutant	SDH-Deficient
Frequency	~80%	~10%	~5%
IHC Profile	KIT+, DOG1+	KIT-, DOG1+	KIT (Var), SDHB Lost
Morphology	Spindle (Classic)	Epithelioid	Epithelioid
Primary Site	Any GI Site	Stomach	Stomach
Treatment	Imatinib	Avapritinib (D842V)	Temozolomide/Trials

7. What is the Diagnostic Algorithm for Mesenchymal GI masses?

A systematic approach is required to differentiate GIST from other mesenchymal mimics like Leiomyomas or Schwannomas.

Flowchart outlining a step-by-step immunohistochemistry (IHC) approach to diagnose gastrointestinal stromal tumors (GIST) variants, including testing for KIT (CD117) and DOG1 markers, and further steps for PDGFRA GIST and SDHB IHC.

Algorithmic approach starting with KIT/DOG1 and progressing to SDHB.
Theory Content: If KIT, DOG1, and SDHB (intact) are all negative, the differential diagnosis expands to Desmoid tumors ($\beta$-catenin+) or Solitary Fibrous Tumors (STAT6+).

8. Conclusion: The clinical necessity of DOG1

DOG1 (Discovered on GIST-1) has become an essential marker because it remains positive in the majority of KIT-negative PDGFRA cases.

A flowchart summarizing diagnostic steps for GIST, emphasizing simultaneous testing for KIT and DOG1, and outlining interpretations for PDGFRA mutations and SDHB IHC results.

Theory Content: Dual testing (KIT + DOG1) is the clinical gold standard to prevent misdiagnosis of Imatinib-resistant PDGFRA variants.

9. High – yield MCQS

10. Exam pearl and key takeaways

DOG1 is more than just a backup for KIT; it is a mandatory marker for identifying the Imatinib-resistant PDGFRA D842V variant.

Modern GIST pathology is defined by the IHC Triple Play (KIT/DOG1/SDHB) followed by targeted molecular sequencing to ensure precision TKI therapy.

View this post on Instagram

11.Ready to Master This Topic?

Join NEET-SS Oncopathology course Join FRCPath Part 1 Histopathology course Join FRCPath Part 2 Histopathology